Home
中文
English தமிழ் Português 中文 Tiếng Việt Filipino ਪੰਜਾਬੀ 自动翻译 — 英文版本为权威版本。
机器翻译，已经临床审核。

杜普伊特伦挛松解术 资料

机器翻译，已经临床审核。

本方案由基兰·希尔帕拉（Kieran Hirpara）医生指导，用于您在罗克汉普顿 Mater 私人医院接受杜普伊特伦挛缩（腱膜切除术）手术释放后的康复过程。获得良好疗效的两个支柱是夹板（在愈合期间保持已松解的手指伸直）和锻炼计划（保持手指活动）。请将此页面或其 PDF 文件带给您的手部治疗师，以确保您的康复过程协调一致。

如果您对术后伤口有任何疑虑，请联系诊所。拍摄伤口照片并通过电子邮件发送以供审查通常很有帮助。

预期情况

杜普伊特伦挛缩症手术会切除将手指拉向手掌的病变索带，恢复手指伸直的能力。该疾病本身已在杜普伊特伦挛缩症页面中说明；目前无根治方法，手术的目标是切除病变组织并恢复手指伸直功能。

您通常会在术后2–3天被转诊至手治疗师。治疗师会为您制作一个定制的塑料夹板，将手术手指固定在伸直（笔直）位置，并指导您开始以下温和的锻炼计划。夹板与锻炼相辅相成：夹板保护手术获得的伸直状态，而锻炼则保持手指屈曲活动度，防止僵硬。

在拆线前，请保持伤口清洁干燥。拆线后，您可以让皮肤沾水，但接下来的一周内避免浸泡或将手浸入水中。诊所的伤口护理页面详细说明了敷料、感染迹象及疤痕护理。杜普伊特伦挛缩症术后疤痕按摩非常重要，待伤口愈合后，您的治疗师会指导您进行。

疤痕护理

在杜普伊特伦挛缩手术后最初几周，手掌处的疤痕通常质地较硬、隆起且触痛，随后在接下来的几个月里逐渐变软并淡化。疤痕按摩是澳大利亚手部治疗护理的常规组成部分：一项针对认证手部治疗师的全国性调查显示，几乎所有治疗师在手部手术后均会使用该方法（通常在拆线、伤口完全愈合后开始，约在此时），以软化疤痕、改善皮肤在下方组织上的滑动性，并缓解疤痕敏感，通常联合使用硅胶凝胶或硅胶贴片，而非单独使用 [6]。目前关于疤痕按摩的研究证据仍在发展中，但现有证据支持其用于减轻疤痕相关不适并改善活动度 [6]。您的治疗师将向您演示具体手法，并可能建议配合使用硅胶产品，通常夜间佩戴夹板时同时使用。

恢复、工作与长期预后

肿胀和僵硬在术后早期属正常现象，随着手部活动会逐渐缓解；舒适度、活动范围和握力通常在数月内持续改善。在术后早期保持手部抬高并轻柔活动，有助于减轻肿胀并防止小关节僵硬。手术中获得的伸直度在此期间通常能良好维持。在一项关于杜普伊特伦挛缩松解术后康复的随机对照试验中，大多数接受手术的手指在术后前三个月的手部治疗期间保持或改善了其伸直功能 [2]。

停工时间取决于您的手部工作性质。在一项针对 2,500 多名接受杜普伊特伦病治疗患者的研究中，开放筋膜切除术后的中位复工时间约为两周，约十分之九的患者在一年内重返工作岗位；体力要求较高的工作所需时间更长 [4]。Hirpara 医生将在复诊时与您讨论适合您具体工作情况的复工时间；较重的体力劳动通常需待伤口牢固愈合且握力舒适后方可进行。

由于杜普伊特伦病是一种终身性疾病，随着时间推移，部分紧绷感可能会复发，且由于对复发的定义不同，各研究报告的复发率差异很大。长期预后总体令人放心：在一项采用现代共识定义对 142 例筋膜切除术进行约四年随访的研究中，真正发生挛缩复发的比例约为 3–4%，尽管约三分之一的患者仍保留一定的残余弯曲，但通常程度较轻，且远未达到手术矫正前的挛缩程度 [5]。夹板、疤痕护理和锻炼计划均旨在保护您的手术效果；如果任何手指在任何时候开始出现再次紧绷，请告知诊室。

您的夹板

  • 第一周左右： 白天和夜间均佩戴夹板，仅在您进行锻炼（以及获准清洗时）取下。
  • 第一周后： 大多数人改为仅在夜间佩戴夹板，并可在白天开始用手进行轻度活动。
  • 夜间佩戴夹板持续约 3 个月（在某些情况下长达 6 个月），以保护手指在组织成熟过程中不向掌心回缩。
  • 您的手部治疗师和 Hirpara 医生将根据您的具体情况提供关于夹板佩戴时间和活动的具体建议。上述时间为常规模式，并非固定规则。

佩戴夹板期间严禁驾驶。 当您改为仅在夜间佩戴夹板后，只要感觉舒适且能安全握住方向盘，即可恢复白天驾驶。

致您的物理治疗师 / 手部治疗师：

管理

  • 术后 2–3 天转诊，以制作热塑性伸展夹板
  • 夹板佩戴方案：第一周左右白天和夜间均佩戴（锻炼时取下），随后仅在夜间佩戴，白天进行轻度功能性活动；夜间佩戴夹板持续约 3 个月（必要时长达 6 个月），根据外科医生/治疗师的评估调整
  • 家庭锻炼计划如下述卡片所示：主动伸展、固定远端指间关节（DIP）屈曲、在笔上进行的远端指间关节（DIP）/近端指间关节（PIP）屈曲、复合屈曲、腕关节腱固定作用
  • 伤口护理遵循诊所的伤口护理指南；愈合后进行瘢痕管理
  • 重复次数和每日频率由主治治疗师设定

注意事项

  • 保持伤口清洁干燥，直至拆线；拆线后一周内避免浸泡/浸入水中
  • 夹板依从性对于维持手术获得的伸展角度至关重要
  • 佩戴夹板期间严禁驾驶

这些是您讲义中的锻炼动作，由您的手部治疗师指导开始，并在家中继续练习。

您的练习

术后方案

本方案与注册手部治疗师、Extend 康复中心的 Ruby Doolan 共同制定。本方案与诊所的一般康复建议配合使用：请参阅 术后疼痛管理、伤口护理 和 手部治疗基础。关于手术本身，请参阅 杜普伊特伦筋膜切除术。

上述康复预期、重返工作岗位的数据以及疤痕护理指导均摘自杜普伊特伦手术后康复的已发表试验、综述和调查，包括随机试验以及关于筋膜切除术后夹板固定和手部治疗的系统综述 [1–3]。夹板佩戴方案和锻炼计划为本诊所自有方案，由 Hirpara 医生与您的手部治疗师共同商定，您的夹板佩戴时间表将在您的复查中进行个体化调整。

参考文献

[1] Jerosch-Herold C, Shepstone L, Chojnowski AJ, Larson D, Barrett E, Vaughan SP. 杜普伊特伦挛缩筋膜切除术或皮肤筋膜切除术后夜间夹板固定：一项务实的多中心随机对照试验。BMC 肌肉骨骼疾病. 2011;12:136. https://pmc.ncbi.nlm.nih.gov/articles/PMC3146906/ [2] Collis J, Collocott S, Hing W, Kelly E. 杜普伊特伦挛缩手术松解后夜间伸展矫形器的效果：一项单中心随机对照试验。《美国手外科杂志》. 2013;38(7):1285–1294.e2. https://doi.org/10.1016/j.jhsa.2013.04.012 [3] Karam M, Kahlar N, Abul A, Rahman S, Pinder R. 杜普伊特伦挛缩筋膜切除术后伴有或不伴有夹板固定的手部治疗比较：系统综述和荟萃分析。《手部和显微外科杂志》. 2022;14(4):308–314. https://pmc.ncbi.nlm.nih.gov/articles/PMC10042625/ [4] Blake SN, Poelstra R, Andrinopoulou ER, 等. 杜普伊特伦病治疗后重返工作岗位及相关成本。《整形外科与重建外科杂志》. 2021;148(3):580–590. https://pubmed.ncbi.nlm.nih.gov/34292887/ [5] Radhamony NG, Nair RR, Sreenivasan S, 等. 杜普伊特伦掌筋膜切除术后残留畸形与复发——142例的长期随访。《医学与外科年鉴》. 2022;73:103224. https://pmc.ncbi.nlm.nih.gov/articles/PMC8767281/ [6] Scott HC, Robinson LS, Brown T. 瘢痕按摩作为术后瘢痕干预措施：澳大利亚手部治疗师的实践调查。《手部治疗》. 2024;29(1):21–29. https://pmc.ncbi.nlm.nih.gov/articles/PMC10901164/

Reviewed by Dr Kieran Hirpara · 10 June 2026.

Want the clinical detail? Read the clinician version.

Talk to your treating clinician for advice specific to you.

For an appointment with the CQ Hand + Upper Limb team, ask your GP about a referral or visit www.cqupperlimb.com.

Evidence & references

This is the clinical evidence summary written for health professionals. It is technical, and it lists the research this page was built from. You do not need to read it to understand your treatment or to make a decision about it.

Topic scope: post-operative rehabilitation after open excision of diseased palmar/digital fascia for Dupuytren contracture — limited/regional fasciectomy, extending to dermofasciectomy (fascia plus overlying involved skin, replaced with a graft) for aggressive or recurrent disease. The procedure-selection literature (fasciectomy vs needle aponeurotomy vs collagenase) is summarised only as far as it frames recurrence expectations and rehabilitation; the rehab focus is the post-fasciectomy pathway — early active and passive finger extension and flexion, oedema control, scar management, and night extension splinting.

Defining principle of this rehab: fasciectomy removes diseased tissue and restores extension that the disease had taken away — it does not cure the diathesis, and the corrected finger sits in a tissue bed that wants to contract back. So the rehab is a "regain-and-hold" pathway: early motion to keep the freed joints supple and prevent the new flexor-tendon and skin-glide planes from binding down, oedema and scar control so the soft tissues mature without tethering, and a night extension orthosis to defend the surgical correction during healing. The defining clinical question is not whether a construct needs protection (there is no construct), but how aggressively to splint — and here the evidence has shifted decisively toward selective, not routine, splinting.

A. PROCEDURE OUTCOMES & RECURRENCE (context for the rehab)

Open partial (limited) fasciectomy is the long-standing reference operation for Dupuytren contracture and gives the most durable correction of the three mainstream options:

  • Correction is reliable and recurrence is the dominant long-term limitation. Across modern series the operation restores extension well, but Dupuytren is a lifelong diathesis and some tightening returns over years. Reported recurrence rates vary enormously because studies define recurrence differently (any palpable disease vs a threshold extension loss vs need for re-intervention). Using the modern consensus definition, true recurrence of contracture is low at medium-term follow-up, though a substantial minority retain mild residual curvature well short of the pre-operative deformity [corpus: jhsa.2012.06.032; literature: Radhamony 2022].
  • Fasciectomy vs minimally invasive options. Compared with needle aponeurotomy/fasciotomy and collagenase Clostridium histolyticum, open fasciectomy has a longer recovery and higher minor complication rate but lower recurrence — the recurring trade-off in this disease. Needle and collagenase are quicker with faster return to function but recur sooner [corpus: jhsa.2021.05.022; jhsa.2011.08.004; 1753193418786947]. This trade-off is why fasciectomy is typically chosen for denser, multi-ray or PIP-predominant contractures — the same cases whose rehab is hardest and whose splinting is most likely to be justified.
  • Repeat limited fasciectomy for recurrence is safe and effective, supporting fasciectomy as a durable, repeatable mainstay rather than a one-shot procedure [corpus: bjj-2020-1393.r2].

Why this matters for rehab: recovery counselling and splint expectations must be framed against a disease that cannot be cured, only corrected — the rehab protects a correction, it does not prevent the diathesis.

B. THE SPLINTING CONTROVERSY (the central rehab question)

Historically, every patient was issued a static night extension orthosis after fasciectomy on the assumption it preserved the correction. The best available evidence does not support routine splinting — it supports selective splinting for patients who lose extension.

  • Jerosch-Herold 2011 (pragmatic multi-centre RCT, n = 154). Hand therapy alone vs hand therapy + night splinting after fasciectomy/dermofasciectomy. No between-group difference in self-reported function (DASH), finger range of motion, or satisfaction. Authors concluded routine night splinting for all patients is not recommended, reserving it for cases where extension deficits recur [literature: Jerosch-Herold 2011, BMC Musculoskelet Disord].
  • Collis 2013 (single-centre RCT, n = 56). Night extension orthosis + hand therapy vs hand therapy alone after surgical release. No significant difference in total active extension or any secondary outcome at 3 months. Same conclusion: provide an orthosis selectively, when extension loss occurs, not universally [corpus: jhsa.2013.04.012; literature: Collis 2013].
  • Karam 2022 (systematic review + meta-analysis, 4 RCTs, n = 295). Pooling the splint-vs-no-splint trials found no significant difference in total active flexion/extension, DASH, pain, grip or satisfaction. The collective signal is consistent and now moderately strong: adding a splint to good hand therapy does not improve the average outcome [corpus: 1055/s-0041-1725221; literature: Karam 2022].
  • Earlier/smaller work (e.g., post-fasciectomy splinting pilot studies) pointed the same way — splinting is low-yield as a blanket policy [corpus: 1753193412437631].

Practical reading for this protocol. The practice's pattern — splint day-and-night for ~1 week, then night-only with a low threshold to continue (or reinstate) splinting if a finger starts to drift back into flexion — is a reasonable, evidence-aligned middle path: it defends the correction during the highest-risk early healing window and during sleep, while honouring the trial finding that indefinite routine splinting adds little. The trials measured average outcomes; they do not say splinting is useless for the individual who is losing extension, which is exactly the subgroup the authors carved out. This is a defensible selective-splinting stance, not a contradiction of the protocol.

C. HAND-THERAPY & EXERCISE EVIDENCE

  • Early supervised hand therapy is the backbone of recovery and is where the demonstrable benefit lies (the splint trials all compared against a hand-therapy baseline, not against nothing). Active and passive extension and flexion, oedema control and scar management are standard from the first post-operative therapy visit, typically 2–3 days after surgery.
  • Most operated fingers hold or improve their extension over the first three months of hand therapy — the window in which the protocol concentrates splinting and exercise [corpus: jhsa.2013.04.012, control arm; literature: Collis 2013].
  • Scar management. Scar massage is near-universal in hand-therapy practice after Dupuytren surgery to soften the palmar scar, improve skin glide and settle sensitivity, generally combined with silicone gel/sheeting and begun around suture removal once the wound is healed. The supporting evidence is developing rather than definitive but favours reduced scar-related discomfort and improved movement [literature: Scott 2024, Australian hand-therapist survey].
  • Return to work. In a large cohort, median return after open fasciectomy was ~2 weeks with ~90% back at work within the year; physically demanding jobs took longer [literature: Blake 2021].
  • Pre-operative hand therapy has a thinner evidence base and is not a substitute for the post-operative programme [corpus: 17589983241227162].

Phased rehabilitation timeline (matching the synthesis phases)

Phase Window Splint Movement / use Scar & oedema Notes
I — Protect & mobilise ~Days 2–7 Custom thermoplastic extension orthosis day & night, off for exercises Gentle active extension + active DIP/PIP and composite flexion from the first therapy visit; wrist tenodesis Oedema control (elevation, gentle movement); wound kept clean & dry Therapy referral 2–3 days post-op; splint defends the surgical correction during the highest-risk window
II — Restore motion ~Week 1 → 6–8 Transition to night-only; light functional day use of the hand Progress active + passive extension and flexion; restore full composite fist and full extension Scar massage + silicone once wound healed (around suture removal) Most extension is held or regained through this window; daytime driving resumes once out of the splint and grip is safe
III — Strengthen & return ~Week 6–8 → 3 months Night-only continues ~3 months (up to ~6 months selectively if extension is being lost) Grip and functional strengthening; return to heavier manual work as wound is soundly healed and grip comfortable Ongoing scar maturation over months Splinting beyond this window is selective, driven by extension loss — not routine (see §B)

The phase structure and timings are protocol/consensus, agreed between the surgeon and hand therapist; the trials inform the splinting policy within them, not the exact week boundaries.

D. COMPLICATIONS (rehab-relevant)

  • Flare reaction / early CRPS-spectrum. A proportion of patients develop a post-operative inflammatory "flare" — disproportionate swelling, stiffness, redness and pain — which can progress to complex regional pain syndrome (CRPS type 1). Early recognition, oedema control, gentle continued motion and analgesia matter; CRPS is one of the more feared rehab-derailing complications after hand surgery [corpus: jht.2024.09.002 (Dupuytren CRPS-1 case); hcl.2009.11.001 (CRPS after hand surgery)].
  • Digital nerve / vessel injury. The neurovascular bundles are displaced by Dupuytren cords, especially in recurrent disease and at the PIP; injury is a recognised operative risk. New sensory change post-operatively warrants surgeon review [corpus: hansur.2017.07.002 — complications systematic review; 17531934231206317 — surgical complications/adverse events].
  • Wound healing, haematoma, infection, stiffness. Open fasciectomy has a higher minor-complication rate than the minimally invasive options; meticulous wound care and early motion mitigate stiffness and tethering [corpus: hansur.2017.07.002].
  • Incomplete correction / residual PIP deficit. PIP contractures correct less completely than MCP; residual deficit may persist and is the usual trigger for selective ongoing splinting.

E. KEY CONTROVERSIES / EVIDENCE QUALITY

  1. Routine vs selective splinting — the headline controversy, now reasonably settled toward selective: three RCTs and a meta-analysis show no average benefit from adding a static night orthosis to good hand therapy, with all authors carving out the extension-loss subgroup. The practice's "night-only, low threshold to continue if drifting" approach is consistent with this. Moderate (multiple RCTs + SR/MA).
  2. Recurrence is definition-dependent — headline recurrence figures are not comparable across studies; the consensus definition gives lower, more credible rates. Counsel against the cure expectation. Moderate.
  3. Procedure choice frames rehab — fasciectomy trades a longer recovery and more minor complications for lower recurrence than needle/collagenase. The fasciectomy cohort is, by selection, the harder-rehab cohort. Moderate.
  4. The phase timings are consensus — drawn from surgeon/therapist protocols, not a rehab RCT. The splinting policy within them is trial-informed; the week boundaries are typical, not trial-derived. Weak/consensus.

F. EVIDENCE STRENGTH FLAGS (summary)

  • MODERATE (multiple RCTs + SR/MA): routine night splinting adds no average benefit over hand therapy alone after fasciectomy — splint selectively for extension loss (Jerosch-Herold 2011; Collis 2013; Karam 2022 meta-analysis of 4 RCTs / 295 patients).
  • MODERATE (cohorts / comparative): fasciectomy gives durable correction with lower recurrence but longer recovery and more minor complications than needle aponeurotomy/collagenase; repeat fasciectomy is safe and effective; CRPS and digital-nerve injury are recognised rehab-relevant complications.
  • WEAK / CONSENSUS: the post-operative phase structure and timings themselves (surgeon + hand-therapist protocol; no defining rehab RCT). Scar-massage benefit is supportive but the evidence base is still developing.

CITATIONS

RAG corpus (180,000+ Orthopaedic articles)

  • Correction of contracture and recurrence rates of Dupuytren contracture following fasciectomy. J Hand Surg Am. 2012. DOI: 10.1016/j.jhsa.2012.06.032
  • Repeat limited fasciectomy is a safe and effective treatment for recurrence of Dupuytren's contracture. Bone Joint J. 2021. DOI: 10.1302/0301-620X.103B5.BJJ-2020-1393.R2
  • Limited fasciectomy versus collagenase Clostridium histolyticum for Dupuytren contracture. J Hand Surg Am. 2021. DOI: 10.1016/j.jhsa.2021.05.022
  • The efficacy and safety of fasciectomy and fasciotomy for Dupuytren's contracture. J Hand Surg Eur. 2011. DOI: 10.1177/1753193410397971
  • Cost-effectiveness of open partial fasciectomy, needle aponeurotomy, and collagenase injection for Dupuytren contracture. J Hand Surg Am. 2011. DOI: 10.1016/j.jhsa.2011.08.004
  • Three-year recurrence of Dupuytren's contracture after needle fasciotomy and collagenase injection. J Hand Surg Eur. 2018. DOI: 10.1177/1753193418786947
  • The effect of night extension orthoses following surgical release of Dupuytren contracture: a single-centre RCT. J Hand Surg Am. 2013. DOI: 10.1016/j.jhsa.2013.04.012
  • Comparison of hand therapy with or without splinting postfasciectomy for Dupuytren's contracture: systematic review and meta-analysis. J Hand Microsurg. 2022. DOI: 10.1055/s-0041-1725221
  • Does use of a night extension orthosis improve outcomes in patients with Dupuytren contracture? J Hand Surg Glob Online. 2021. DOI: 10.1016/j.jhsg.2021.05.001
  • A pilot study assessing the effectiveness of postoperative splinting after limited fasciectomy. J Hand Surg Eur. 2012. DOI: 10.1177/1753193412437631
  • Pre-operative hand therapy management of Dupuytren's disease: a systematic review. Hand Ther. 2024. DOI: 10.1177/17589983241227162
  • Current concepts in the management of Dupuytren disease of the hand. J Am Acad Orthop Surg. 2020. DOI: 10.5435/JAAOS-D-20-00190
  • Complications after treating Dupuytren's disease: a systematic literature review. Hand Surg Rehabil. 2017. DOI: 10.1016/j.hansur.2017.07.002
  • Surgical complications: errors and adverse events (hand surgery). J Hand Surg Eur. 2023. DOI: 10.1177/17531934231206317
  • The case of a woman with bilateral Dupuytren's contractures who developed CRPS-1. J Hand Ther. 2024. DOI: 10.1016/j.jht.2024.09.002
  • Complex regional pain syndrome after hand surgery. Hand Clin. 2009. DOI: 10.1016/j.hcl.2009.11.001

Splinting & hand-therapy literature (URLs)

  • Jerosch-Herold C, Shepstone L, Chojnowski AJ, et al. Night-time splinting after fasciectomy or dermo-fasciectomy for Dupuytren's contracture: a pragmatic, multi-centre, randomised controlled trial. BMC Musculoskelet Disord. 2011;12:136. https://pmc.ncbi.nlm.nih.gov/articles/PMC3146906/
  • Collis J, Collocott S, Hing W, Kelly E. The effect of night extension orthoses following surgical release of Dupuytren contracture: a single-centre, randomised, controlled trial. J Hand Surg Am. 2013. https://pubmed.ncbi.nlm.nih.gov/23790420/
  • Karam M, Kahlar N, Abul A, et al. Comparison of hand therapy with or without splinting postfasciectomy for Dupuytren's contracture: systematic review and meta-analysis. J Hand Microsurg. 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC10042625/
  • Blake SN, Poelstra R, Andrinopoulou ER, et al. Return to work and associated costs after treatment for Dupuytren's disease. Plast Reconstr Surg. 2021. https://pubmed.ncbi.nlm.nih.gov/34292887/
  • Radhamony NG, Nair RR, Sreenivasan S, et al. Residual deformity versus recurrence following Dupuytren's palmar fasciectomy — long-term follow-up of 142 cases. Ann Med Surg. 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC8767281/
  • Scott HC, Robinson LS, Brown T. Scar massage as an intervention for post-surgical scars: a practice survey of Australian hand therapists. Hand Ther. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC10901164/

Society guidance & published rehab protocols

  • The British Society for Surgery of the Hand (BSSH) — Dupuytren's disease patient and professional guidance. https://www.bssh.ac.uk/patients/conditions/25/dupuytrens_disease
  • BSSH — Assessing the outcome of surgery for Dupuytren's disease of the hand. https://www.bssh.ac.uk/assessing_the_outcome_of_surgery_for_dupuytrens_disease_of_the_hand.aspx
专业协会这些代表什么？→